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Abstract 
Introduction: Malignant pleural effusions (MPE) commonly occur in patients with advanced cancer. 
Drainage of fluid aims to relieve symptoms and improve quality of life.  
Objectives: To improve our understanding of how therapeutic aspiration affects symptoms and 
activities in patients with MPE. 
Method: Patients presenting to the Pleural Clinic at Norfolk and Norwich University Hospital with a 
confirmed or suspected MPE participated in up to three semi-structured interviews during their 
diagnostic/therapeutic pathway. Interviews were analysed using framework analysis, by two 
researchers independently. 
Results: Sixteen patients participated. Symptoms reported before drainage included breathlessness, 
cough, chest pain, fatigue and anorexia. Symptoms affected their activities, including walking, 
bending over and socialisation. Patients described anxiety about the underlying diagnosis and fear of 
over-reliance on others. Expectations of drainage-outcome varied, with some hoping for a cure and 
others hoping for any improvement. After drainage, breathlessness, chest pain and cough improved 
in some patients. They reported feeling and sleeping better, but fatigue and poor appetite remained. 
Participants were more active after aspiration, but the duration of improvement was a few days 
only. Despite this, patients still felt the procedure worthwhile. 
Conclusion: Overall health and respiratory symptoms improved following drainage, but 
constitutional symptoms did not improve. This may be because constitutional symptoms are caused 
by the underlying cancer. This study suggests that clinicians should consider a range of symptoms, 
rather than just breathlessness, in planning outcomes for clinical trials. These results are important 
to inform patients about the potential benefits and duration of symptom improvement after 






A malignant pleural effusion (MPE) is an accumulation of fluid secondary to cancer in the space 
between the lung and chest wall (the pleural space).  It affects around 40,000 people per year in the 
UK1. MPE indicates advanced, incurable cancer. It can develop in patients with known cancer or be 
the first presentation of a new diagnosis. It can be due to primary mesothelial cancer 
(mesothelioma) or spread of cancer from another site. Median survival from diagnosis is around 3 to 
12 months2. Treatment focuses on palliating symptoms and improving quality of life. 
Following detection of a pleural effusion, patients are usually referred to a Pleural Clinic for pleural 
fluid aspiration to aid diagnosis and treatment. Therapeutic aspiration is drainage of a large volume 
of pleural fluid to relieve symptoms, usually done as an outpatient over about ten minutes. If fluid 
and symptoms recur, then a definitive pleural procedure (e.g. chest drain and pleurodesis or 
indwelling pleural catheter insertion) is performed to provide long term symptom control1.  
Randomised controlled trials (RCTs) aimed at comparing treatments to improve symptoms in 
patients with MPEs have focussed on breathlessness, often assessed using a visual analogue scale3-7. 
However, not all patients recruited to these trials were assessed as being breathless at baseline and 
a significant proportion did not experience improvement in breathlessness following pleural fluid 
drainage. Trial data also demonstrates that patients experience improvements in chest pain 
following drainage3. These data suggest that we should consider a broader range of symptoms and 
benefits when considering whether to drain a patient’s effusion. 
The main aim of this study was to improve our understanding of symptoms in patients with known 
or suspected MPE undergoing therapeutic aspiration and the impact of aspiration on those 
symptoms. Further aims were to explore the impact this has on patients’ activities, psychosocial 
aspects and their experience of the procedure itself and whether this varied in significant 
subcategories (gender or underlying cancer type). The findings will influence design of future RCTs 
and advice given to patients. 
Methods 
Sequential patients were recruited from the Pleural Clinic at the Norfolk and Norwich University 
Hospital, Norwich, UK between January and April 2019. The study was ethically approved by the 
Greater Manchester West Research Ethics Committee (IRAS ID: 248840) and undertaken in 
accordance with Good Clinical Practice guidelines. Patients presenting with a new pleural effusion or 
referred for therapeutic aspiration were screened for eligibility. Eligibility criteria were: adults with a 
known or suspected MPE diagnosed on chest radiograph, computer tomography scan or ultrasound; 
attending for therapeutic aspiration; and able to fulfil all study requirements. Exclusion criteria were: 
visual impairment; conditions requiring chest drain insertion; known transudative pleural effusion; 
and effusion thought to be primarily due to cardiac, renal or hepatic impairment.  
Patients gave written informed consent and then participated in up to three brief focused semi-
structured interviews during their therapeutic (and diagnostic) pathway. The interviews were 
performed by one of two doctors (CT and RF) who were not otherwise involved in the patient’s care. 
Each interviewer performed all interviews for each individual. Interviews took place in a clinic room 
adjacent to the procedure room. The first interview was prior to their initial therapeutic aspiration 
and focussed on symptoms, the impact of those symptoms on activities and expectations of 
therapeutic aspiration and lasted approximately fifteen minutes. The second interview was 
conducted approximately seven days later, prior to the follow-up clinic appointment at which 
patients would be reassessed and receive their results. This focussed on how therapeutic aspiration 
had affected their symptoms and activities and their experience of drainage and lasted 
approximately ten minutes. A third interview was conducted if the participant required a further 
drainage procedure (unless this was performed at the time of the follow-up appointment). This 
interview focussed on change in symptoms and activities and, if appropriate, how these had led the 
patient to seek a further drainage procedure. It lasted five to ten minutes. Relatives also participated 
in the interviews if they and the patient wanted, and these relatives gave verbal consent for the use 
of their contributions. 
A topic guide was followed to ensure all relevant points were addressed. Interviews were audio-
recorded, transcribed verbatim, anonymised and analysed by two researchers independently (CT 
and RF) using framework analysis8. The results were then compared, discussed and collated. 
Recruitment stopped once data saturation occurred9.  
Results 
Sixteen patients were recruited to the study (Figure 1): 12 men and 4 women. Demographics are 
summarised in Table 1. All patients completed the first interview, thirteen the second and two the 
third. 
Symptoms prior to aspiration 
Patients described a range of symptoms before drainage, included respiratory symptoms, such as 
breathlessness, cough and chest pain, and constitutional symptoms including anorexia and fatigue. 
However, no symptoms (including breathlessness) were reported by all patients. Other symptoms 
included wheezing and change in voice.  
“If the coughing was to stop and go away, I would be back to normal.” (83, male, metastatic 
carcinoid tumour) 
Symptoms were exacerbated by lying flat, leading to difficulty sleeping. 
"The worst is sleeping because… if you lie down, the tendency to cough is augmented quite 
significantly." (81, male, lymphoma) 
Activity prior to aspiration 
Patients described how these symptoms affected their daily life and activities, naming several 
different activities including housework, gardening and climbing stairs. Several sports were 
mentioned including golf and hiking. There was wide variation in the range of activities that patients 
mentioned as making them breathless, from minimal exertion (e.g. on talking) to significant activity 
(e.g. on running). These were activities that they had previously been able to do without 
breathlessness. 
"I've been getting breathless with climbing the stairs at home. I used to do a lot of walking 
and um walking up hill made me breathless and its now walking on a level at a reasonable 
speed I get breathless too" (75, male, mesothelioma) 
Bending over often exacerbated symptoms such as breathlessness and cough. Patients referred to 
this in relation to activities.   
"Quite uncomfortable when I bend over. I like to pick my little dog up." (85, female, 
metastatic lung cancer) 
Expectations of therapeutic aspiration 
Some patients had high expectations of therapeutic aspiration and were hoping for a cure or to feel 
normal again. 
"I’m hoping for miraculously to get me back to where I was… get rid of the breathlessness 
and coughing and carry on with my life." (75, male, mesothelioma) 
Other patients felt that any improvement would be worthwhile. Some mentioned specific factors 
that they felt might limit the benefit they gained, such as their age or comorbidities. 
“Anything better than I got at the moment.” (69, male, mesothelioma) 
Some patients named specific symptoms they hoped would improve, including breathlessness, 
cough and fatigue. 
"Well I’m hoping that it will make me less breathless and I also hope it will subdue the cough 
which it theoretically ought to." (81, male, lymphoma) 
Patients also described activities they hoped to be able to do after drainage. Walking was mentioned 
as important as it facilitated other activities. 
"Yeah, just get more mobile with my son really. Just get more comfortable and be able to get 
walking – just, you know, get up the road with my dog." (45, female, metastatic breast 
cancer) 
Patients described frustration at not being able to do certain activities and the effect of this on their 
emotional well-being and quality of life. 
"And you can tell by the way I'm talking how my quality of life is. I can barely walk over there. 
You know, it is a lovely sunny day and I'd like to be out enjoying it.” (70, male, metastatic 
pancreatic cancer) 
Psychosocial impact of MPE 
Patients spontaneously described the psychological and social impacts of MPE during the interviews. 
Several patients mentioned anxiety regarding their underlying diagnosis. This was seen both in 
patients with known malignant diagnoses and those without. 
"I think cause we’re so apprehensive about what it is that we can’t really think of anything 
else can we.” (Wife of male participant aged 75, mesothelioma, diagnosis not known at 
interview) 
Another recurrent theme was lack of motivation, with some patients relating this to low mood or to 
fatigue. 
"It sucks you down so far that you kind of go "oh, it's ok, it's alright." And you just sit on the 
loo ‘cause you can't be arsed to get off." (70, male, metastatic pancreatic cancer) 
Patients often identified alternative explanations for their symptoms, attributing them to other 
diagnoses, such as COPD, or to a particular event such as a fall, or to ageing. 
“I had been diagnosed with COPD and I put everything down to that at first you see.” (85, 
female, metastatic lung cancer) 
Patients described how being unwell conflicted with their view of themselves as fit and healthy, 
sometimes expressing this as a loss. 
"Well I've never been ill before, I can't believe I'm like this. I've been so fit and healthy." (81, 
female, metastatic breast cancer) 
A common fear among patients was reliance on others and becoming a burden.  
"I don't like her pushing me [in the wheelchair] ‘cause she has osteoporosis you know. I don’t 
want to put too much strain on her" (79, male, mesothelioma) 
Experience of therapeutic aspiration 
The experience of the procedure itself varied widely. A common (but not universal) complaint was 
pain. Variation was seen within patients who had more than one therapeutic aspiration, with one 
participant describing his second procedure as much more painful than his first. One participant felt 
his pre-procedure warning to expect discomfort rather than pain was inaccurate. However, the 
procedure was generally considered to be tolerable. 
'Not very pleasant. That did hurt when they pushed in at the end, it did hurt. But you put up 
with it.' (81, female, breast cancer) 
A common theme among patients was the significance to them of the volume of fluid, with many 
expressing shock at the volume drained. Some patients expressed their expectations for the 
procedure in terms of the amount of fluid removed, describing a wish for all the fluid to be drained. 
Patients who had only had part of their effusion drained were disappointed that residual fluid 
remained. 
"At first, I was rather shocked cause you drained a litre." (81, male, lymphoma) 
Symptoms following aspiration 
Following aspiration, patients generally saw an improvement in respiratory symptoms, such as 
breathlessness, cough and chest pain. 
"Yeah I was feeling fine after I had it done. Breathing had gone back to normal really" (66, 
male, mesothelioma) 
Sleep also improved. However, some patients were disappointed and hoped for a greater 
improvement in symptoms. 
"Well the only dream I had which wasn’t entirely fulfilled was that the cough would be quite 
substantially diminished." (81, male, lymphoma) 
Generally constitutional symptoms such as anorexia and fatigue remained after therapeutic 
aspiration, even if sleep improved. 
'All I know was getting very tired. I could have a good night's sleep I could and then I could sit 
in my chair and by half past nine I could be off.' (79, male, mesothelioma) 
Rather than naming specific symptoms, some patients described generally feeling better after 
therapeutic aspiration. 
"It really felt better and normal again." (45, female, metastatic breast cancer) 
The duration of benefit was generally only a few days and by their second interview, seven days 
post-procedure, many patients felt their symptoms were back to their pre-procedure baseline. 
Despite this, patients felt the procedure was worthwhile. 
'What you go through is worthwhile if you come out as good as I think I've come out.' (83, 
male, metastatic carcinoid tumour)  
Activity following aspiration 
Patients were generally more active after drainage. Some used their experience of attending the 
hospital for their second visit to gauge their activity levels, comparing how easy it had been to walk 
from their car to the clinic room or whether they had needed to use a wheelchair.  
"We’ve done enough walking this morning… and I haven’t found, like I did say last Monday 
that I was almost ready to want a stop for 5 minutes." (83, male, metastatic carcinoid 
tumour) 
However, some patients restricted their activity levels to avoid over-exerting themselves. 
"I don’t go out of my way to test whether I’m going to get out of breath or not.” (81, male, 
lymphoma)  
Inability to do certain activities was contextualised by its effect on a participant’s social life and 
identity, such as being unable to benefit from the social aspect of playing golf, or other social 
activities.  
"I used to lead walks of 5, 6, 7 miles and I got back up to doing about 3 and a half miles and 
then this breathlessness started and I’m lucky if I can do half a mile now" (75, male, 
mesothelioma) 
Another restriction on social activities was breathlessness when speaking, which one participant 
mentioned improved significantly after drainage. 
" I can hold a conversation now with somebody without getting out of breath, so things must 
have improved which I’m very grateful for." (83, male, metastatic carcinoid tumour) 
Post hoc sub-group analyses 
Due to the male predominance of the sample group, sub-group analysis was performed to compare 
responses of male and female patients. No clear differences were identified between the responses 
of the male and female patients, with similar themes emerging from each. Sub-group analysis also 
failed to find any substantial differences in themes or symptoms from patients with mesothelioma, 
compared to other diagnoses. 
Responses from patients with a known diagnosis of active cancer at the point of recruitment did 
show some differences to those without a known diagnosis. These patients showed more awareness 
of the palliative intention of the procedure, with one participant specifically mentioning his desire to 
improve his quality of life.  
“I’m trying to aspire to, for as long as I can, this quality of life that you guys keep talking 
about.” (70, male, metastatic pancreatic cancer diagnosed before recruitment) 
Their confirmed diagnosis was also reflected in their concerns about their underlying diagnosis and 
potential prognosis. However, the symptoms and limitations in activities they described, and their 
experience of the procedure itself, were broadly similar to those of other patients. 
Discussion 
This prospective study is the first to use semi-structured interviews with patients with known or 
suspected MPE before and after therapeutic aspiration. We found patients experienced a wide 
variety of symptoms causing significant impairment of activity.  
Our results showed that breathlessness, chest pain and cough are common symptoms in patients 
with MPE prior to aspiration, but no single symptom was universally experienced by all patients. This 
is in keeping with a previous study reporting symptoms in patients with MPE undergoing 
thoracoscopy10. Of note, none of our patients mentioned sweating, despite a previous study which 
found one third of patients with mesothelioma experience sweating11. Patients were limited in their 
activities, in keeping with previous work which has demonstrated that patients with MPE are 
sedentary for much of their time, spending a mean of just 9.5 minutes daily doing moderate or 
vigorous physical activity in one actigraphy-based study12.  
Prior to therapeutic aspiration, patient expectations generally fell into two categories, with patients 
wanting either complete relief of their symptoms or feeling that any improvement would be 
worthwhile. This is in keeping with our previous work designed to determine the minimal important 
difference in the visual analogue scale for dyspnoea13. Although the interview guide was designed to 
explore symptoms and activities, patients commonly spontaneously raised psychosocial issues, such 
as low mood, anxiety and a feeling of over-reliance on other people. This demonstrates the 
importance of these issues for patients. Low mood and anxiety are common in patients with cancer, 
including mesothelioma14.  
In keeping with previous research, breathlessness and chest pain decreased following pleural fluid 
drainage3. Secondary to this, patients often experience an improvement in sleep, increased activity 
and quality of life3, 12, 15, 16. Constitutional symptoms, such as fatigue and anorexia, did not improve 
following aspiration, probably because they are caused by the underlying cancer rather than the 
MPE. The duration of symptom relief following therapeutic aspiration was only a few days only, 
which was a novel finding, but there has been previous data demonstrating that recurrence of 
symptoms predicts need for further drainage17. Activity levels increased, in keeping with previous 
findings. Although some patients found the procedure painful, overall patients felt it worthwhile. 
The strengths of this study include the contemporaneous nature of the data collection in relation to 
the patients’ diagnostic and treatment pathway. We were therefore not reliant on patients’ 
recollection of symptoms and how they changed. Furthermore, the use of the semi-structured 
interviews allowed the discussion to be led by the patient and include topics they felt significant, 
particularly the psychosocial impact of MPEs. 
A potential limitation of our study is the male predominance of the sample. This may partially reflect 
the relatively high incidence of mesothelioma in the East of England18. Mesothelioma predominantly 
affects males, due to occupational asbestos exposure e.g. plumbers, builders. However, sub-group 
analysis demonstrated no key differences in the topics raised in the interviews of male patients 
compared to female patients or in patients with mesothelioma compared to other diagnoses. 
Another potential limitation is the small proportion of patients who had a third interview (figure 1). 
However, analysis of the two third interviews that were conducted did not reveal any new themes or 
symptoms.  
These results have implications for the design of future RCTs aimed at determining optimal 
treatment of patients with MPEs. Previous RCTs have chosen patient reported outcome measures 
(PROMs) of breathlessness as the primary outcome measure3, 6. However, our results show that not 
all patients are breathless, and that breathlessness is not the only symptom that improves with 
drainage. Future RCTs should study a wider range of symptoms (e.g. chest pain, cough, sleep) to fully 
explore the benefits of fluid drainage. Our results demonstrated improvement in activity levels 
following aspiration, but there was a wide variation in the specific activities identified and in the 
level of exertion required to perform those activities (e.g. propelling a wheelchair versus running). 
This is an important outcome for patients and may be appropriate to use as an outcome in future 
RCTs, but the optimal way to assess this has not been identified. Some studies have used the Borg 
score following standardised activity, but this group of frail patients may be unable to do even low 
amounts of activity leading to low levels of data completeness17. Some PROMs use ability to perform 
specific activities as a measure of breathlessness e.g. the lung cancer module of the European 
Organisation for the Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-
LC13) asks about breathlessness at rest, on walking and climbing stairs19. Our results show that there 
are no activities performed by all patients which they identify as being impaired by breathlessness. 
This means that it is difficult to identify generic activities common to this group of patients that 
could be used as the basis for a PROM. Actigraphy may be a more appropriate a way of measuring 
patients’ overall physical activity in a research context, rather than questionnaires focusing on 
specific activities12.  
This study has implications for the management of individual patients. It demonstrates the need to 
consider a wide range of symptoms, rather than just breathlessness, when considering who may 
benefit from fluid drainage. Anxiety and low mood are common, and it may benefit patients if we 
identify these problems and offer treatment and support during their pathway, as has been used in 
other cancer pathways20. It may be helpful to identify what important activities a patient struggles to 
perform, and work with them to help them achieve this.  
Current guidelines advise that patients with a prognosis of less than 28 days should be managed 
with therapeutic aspiration only, rather than be offered a definitive procedure5. Our data 
demonstrate that this will not provide lifelong symptom relief, even in this poor prognosis group of 
patients. Despite this short duration of benefit and the discomfort and inconvenience of undergoing 
therapeutic aspiration, most patients viewed the procedure as worthwhile. This information should 
aid patient decision making, an important element of patient centred end of life care21.  
More information prior to aspiration may enable clinicians to better manage patient expectations. 
Some patients had unrealistic expectations of the benefits of therapeutic aspiration, e.g. that 
appetite and energy levels would improve or that it would cure the underlying condition. Patients 
focused on the volume of fluid drained and expressed disappointment if it was not all drained. 
Information should include the symptoms which may and may not improve, the reasons for doing 
the procedure and limitations as to the amount of fluid that can be drained during therapeutic 
aspiration5.  
Further research is necessary to determine the frequency of these symptoms in patients with MPEs 
and in what proportion of patients they improve following fluid drainage. Potentially, this could lead 
to validation of an existing PROM in this subgroup of patients or development of an MPE specific 
PROM.  
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Table 1: Summary of participant demographics 
Total 16 
Mean age (years) (SD) 69 (17.1) 
Sex male: female 12:4 
Diagnosis at recruitment known cancer: 
undiagnosed pleural effusion 














4    
1       
Baseline breathlessness on VASD (n=7)/mean (mm) 57 
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